Literature DB >> 12428105

NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies.

Sylvie Dunoyer-Geindre1, Philippe de Moerloose, Béatrix Galve-de Rochemonteix, Guido Reber, Egbert K O Kruithof.   

Abstract

Antiphospholipid antibodies (aPLA) are associated with thrombophilia and recurrent pregnancy loss. They bind directly to anionic phospholipids or via phospholipid-binding proteins such as beta(2)-glycoprotein 1 (beta(2)GP1). The underlying mechanisms by which aPLA induce a thrombophilic phenotype are not well understood. The present work was done to determine whether antibodies to beta(2)GP1 activate endothelial cells (EC) and whether NFkappaB is involved in this activation. Incubation of EC with these antibodies resulted in a redistribution of NFkappaB from the cytoplasm to the nucleus after a delay of several hours. This was accompanied by an increased expression of tissue factor and of the leukocyte adhesion molecules ICAM-1, VCAM-1 and E-selectin. Inhibition of the nuclear translocation of NFkappaB abolished the response to these antibodies. In comparison to anti-beta(2)GP1 antibodies, incubation of EC with TNF resulted in a more rapid (within 30 minutes) redistribution of NFkappaB and a more pronounced expression of tissue factor and of the leukocyte adhesion molecules. The slower response to the antibodies as compared to TNF suggests that the NFkappaB response to anti-beta(2)GP1 antibodies is indirect. Taken together our results imply that NFkappaB is an essential intermediate in the activation of EC by anti-beta(2)GP1 antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428105

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  26 in total

Review 1.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 3.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

4.  Delayed catastrophic antiphospholipid syndrome after massive cerebral infarction.

Authors:  Wei Hsi Chen; Hung Sheng Lin; Yi Fen Kao; Jia Shou Liu
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

5.  C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.

Authors:  Al Carrera-Marín; Z Romay-Penabad; E Papalardo; E Reyes-Maldonado; E García-Latorre; G Vargas; T Shilagard; S Pierangeli
Journal:  Lupus       Date:  2012-08-29       Impact factor: 2.911

6.  Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors.

Authors:  Kristi L Allen; Anne Hamik; Mukesh K Jain; Keith R McCrae
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

Review 7.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

8.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state.

Authors:  Jakub Swadzba; Teresa Iwaniec; Jacek Musial
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

9.  Association of the 98T ELAM-1 polymorphism with increased bleeding after cardiac surgery.

Authors:  Ian J Welsby; Mihai V Podgoreanu; Barbara Phillips-Bute; Richard Morris; Joseph P Mathew; Peter K Smith; Mark F Newman; Debra A Schwinn; Mark Stafford-Smith
Journal:  J Cardiothorac Vasc Anesth       Date:  2010-01-06       Impact factor: 2.628

Review 10.  Annexin A2: biology and relevance to the antiphospholipid syndrome.

Authors:  E Cockrell; R G Espinola; K R McCrae
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.